On July 31, SKB BIO rose 3.78% in regular trading, trading at 498.4 HKD/share, with turnover of approximately HKD 68.16 million.

On the news front, the company announced on July 30 that a new indication application for its core product sacituzumab tirumotecan (TROP2 ADC) for first-line treatment of recurrent or metastatic triple-negative breast cancer with PD-L1 CPS less than 10 or prior PD-1/PD-L1 inhibitor exposure has been accepted by NMPA and included in the priority review program. This marks the sixth indication application accepted for the product, which already has four approved indications in China and is the first TROP2 ADC globally approved for a lung cancer indication.

Additionally, partner Merck recently initiated a Phase II clinical study (MK-2010-003) evaluating sacituzumab tirumotecan combined with PD-1/VEGF bispecific antibody MK-2010 in advanced solid tumors, further expanding the combination therapy pipeline and signaling deeper global collaboration.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)